Eyding D, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and SSRI. BMJ 2010;341:c4737
Reboxetine is no more effective than placebo for major depressive disorder.
Tag: reboxetine
Jan 19 2011
Reboxetine for acute treatment of major depression
- By Michael Tam in Drug trial, Meta-analysis, Psychiatry, Systematic review
-
19 January 2011
Permanent link to this article: https://evidencebasedmedicine.com.au/?p=250
Categories
Recent Posts
- N95 respirators vs surgical masks to prevent transmission of respiratory tract infections to staff in primary care
- Palmitoylethanolamide (PEA) as treatment for knee osteoarthritis pain
- Duloxetine as treatment for knee osteoarthritis pain
- Isopropyl alcohol nasal inhalation for nausea in adults
- EMDR as treatment for post-traumatic stress disorder
- Oral cimetidine as the treatment of common warts
Archives
Tags
alcohol
antibiotics
antipsychotics
aspirin
atrial fibrillation
BMJ
cancer
cerebrovascular accident
CID
CMAJ
Cochrane
Common cold
coronary heart disease
cryotherapy
depression
DHA
diabetes
EPA
glucosamine
headache
hypertension
influenza
JAMA
knee
Lancet
low back pain
major depression
Medical Observer
migraine
NEJM
NSAID
omega-3
osteoarthritis
pain
pharmaceutical company
PLoS
prophylaxis
salicylic acid
SSRI
statins
subclinical hypothyroidism
UTI
VTE
warfarin
warts
Donate!
We do not accept drug company sponsorship or web based advertising for funding. The operational costs of the website is funded directly by the administrator. Please donate generously to the running costs.
Recent Comments